117 related articles for article (PubMed ID: 19195048)
21. Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials.
Arkenau HT; Arnold D; Cassidy J; Diaz-Rubio E; Douillard JY; Hochster H; Martoni A; Grothey A; Hinke A; Schmiegel W; Schmoll HJ; Porschen R
J Clin Oncol; 2008 Dec; 26(36):5910-7. PubMed ID: 19018087
[TBL] [Abstract][Full Text] [Related]
22. Evolution of capecitabine dosing in colorectal cancer.
Sun W
Clin Colorectal Cancer; 2010 Jan; 9(1):31-9. PubMed ID: 20100686
[TBL] [Abstract][Full Text] [Related]
23. Alternative treatment options in colorectal cancer patients with 5-fluorouracil- or capecitabine-induced cardiotoxicity.
Deboever G; Hiltrop N; Cool M; Lambrecht G
Clin Colorectal Cancer; 2013 Mar; 12(1):8-14. PubMed ID: 23102544
[TBL] [Abstract][Full Text] [Related]
24. Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group.
Porschen R; Arkenau HT; Kubicka S; Greil R; Seufferlein T; Freier W; Kretzschmar A; Graeven U; Grothey A; Hinke A; Schmiegel W; Schmoll HJ;
J Clin Oncol; 2007 Sep; 25(27):4217-23. PubMed ID: 17548840
[TBL] [Abstract][Full Text] [Related]
25. Capecitabine and bevacizumab in heavily pre-treated patients with advanced colorectal cancer.
Larsen FO; Boisen MK; Fromm AL; Jensen BV
Acta Oncol; 2012 Feb; 51(2):231-3. PubMed ID: 21936753
[TBL] [Abstract][Full Text] [Related]
26. Single-agent capecitabine in patients with metastatic colorectal cancer refractory to 5-fluorouracil/leucovorin chemotherapy.
Lee JJ; Kim TM; Yu SJ; Kim DW; Joh YH; Oh DY; Kwon JH; Kim TY; Heo DS; Bang YJ; Kim NK
Jpn J Clin Oncol; 2004 Jul; 34(7):400-4. PubMed ID: 15342667
[TBL] [Abstract][Full Text] [Related]
27. Capecitabine chemotherapy for metastatic colorectal cancer. Chemical structure, combinations and efficacy.
Koukourakis G; Kouloulias V; Zacharias G; Koukourakis M
J BUON; 2010; 15(4):652-9. PubMed ID: 21229625
[TBL] [Abstract][Full Text] [Related]
28. ABCB1 gene polymorphisms are associated with adverse reactions in fluoropyrimidine-treated colorectal cancer patients.
Gonzalez-Haba E; García MI; Cortejoso L; López-Lillo C; Barrueco N; García-Alfonso P; Alvarez S; Jiménez JL; Martín ML; Muñóz-Fernández MA; Sanjurjo M; López-Fernández LA
Pharmacogenomics; 2010 Dec; 11(12):1715-23. PubMed ID: 21142915
[TBL] [Abstract][Full Text] [Related]
29. A meta-analysis of chemotherapy regimen fluorouracil/leucovorin/oxaliplatin compared with fluorouracil/leucovorin in treating advanced colorectal cancer.
Chen ML; Fang CH; Liang LS; Dai LH; Wang XK
Surg Oncol; 2010 Mar; 19(1):38-45. PubMed ID: 19345093
[TBL] [Abstract][Full Text] [Related]
30. Treatment of advanced colorectal carcinoma with oxaliplatin and capecitabine: a phase II trial.
Shields AF; Zalupski MM; Marshall JL; Meropol NJ
Cancer; 2004 Feb; 100(3):531-7. PubMed ID: 14745869
[TBL] [Abstract][Full Text] [Related]
31. Variation in the cost of medications for the treatment of colorectal cancer.
Ferro SA; Myer BS; Wolff DA; Poniewierski MS; Culakova E; Cosler LE; Scarpace SL; Khorana AA; Lyman GH
Am J Manag Care; 2008 Nov; 14(11):717-25. PubMed ID: 18999906
[TBL] [Abstract][Full Text] [Related]
32. Cost-benefit analysis of capecitabine versus 5-fluorouracil/leucovorin in the treatment of colorectal cancer in the Netherlands.
Jansman FG; Postma MJ; van Hartskamp D; Willemse PH; Brouwers JR
Clin Ther; 2004 Apr; 26(4):579-89. PubMed ID: 15189755
[TBL] [Abstract][Full Text] [Related]
33. Preoperative chemoradiotherapy for rectal cancer: a comparison between intravenous 5-fluorouracil and oral capecitabine.
Ramani VS; Sun Myint A; Montazeri A; Wong H
Colorectal Dis; 2010 Aug; 12 Suppl 2():37-46. PubMed ID: 20618366
[TBL] [Abstract][Full Text] [Related]
34. Phase II study of capecitabine in patients with fluorouracil-resistant metastatic colorectal carcinoma.
Hoff PM; Pazdur R; Lassere Y; Carter S; Samid D; Polito D; Abbruzzese JL
J Clin Oncol; 2004 Jun; 22(11):2078-83. PubMed ID: 15169794
[TBL] [Abstract][Full Text] [Related]
35. Bolus 5-fluorouracil as an alternative in patients with cardiotoxicity associated with infusion 5-fluorouracil and capecitabine: a case series.
Saif MW; Garcon MC; Rodriguez G; Rodriguez T
In Vivo; 2013; 27(4):531-4. PubMed ID: 23812226
[TBL] [Abstract][Full Text] [Related]
36. Health economic analysis of fluoropyrimidine-based therapies of colorectal cancer from the perspective of statutory sickness funds.
Grothey A; Kleeberg UR; Stauch M; Hieke K
Z Gastroenterol; 2005 Feb; 43(2):155-61. PubMed ID: 15700205
[TBL] [Abstract][Full Text] [Related]
37. Capecitabine treatment patterns in patients with gastroesophageal cancer in the United States.
Saif MW; Shi N; Zelt S
World J Gastroenterol; 2009 Sep; 15(35):4415-22. PubMed ID: 19764093
[TBL] [Abstract][Full Text] [Related]
38. Pharmacoeconomic benefits of capecitabine-based chemotherapy in metastatic colorectal cancer.
Chu E; Cartwright TH
J Clin Oncol; 2008 May; 26(13):2224-6; author reply 2228. PubMed ID: 18445854
[No Abstract] [Full Text] [Related]
39. Economic evaluation of capecitabine as adjuvant or metastatic therapy in colorectal cancer.
Best JH; Garrison LP
Expert Rev Pharmacoecon Outcomes Res; 2010 Apr; 10(2):103-14. PubMed ID: 20384557
[TBL] [Abstract][Full Text] [Related]
40. Cost minimization analysis of capecitabine versus 5-fluorouracil-based treatment for gastric cancer patients in Hong Kong.
Zhou KR; Cheng A; Ng WT; Kwok TY; Yip EY; Yao R; Leung PY; Lee VW
J Med Econ; 2017 May; 20(5):541-548. PubMed ID: 28277030
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]